Literature DB >> 15576638

Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.

Alec D Weisberg1, Francisco Albornoz, Jane P Griffin, David L Crandall, Hassan Elokdah, Agnes B Fogo, Douglas E Vaughan, Nancy J Brown.   

Abstract

OBJECTIVE: To test the hypothesis that pharmacological plasminogen activator inhibitor (PAI)-1 inhibition protects against renin-angiotensin-aldosterone system-induced cardiovascular injury, the effect of a novel orally active small-molecule PAI-1 inhibitor, PAI-039, was examined in a mouse model of angiotensin (Ang) II-induced vascular remodeling and cardiac fibrosis. METHODS AND
RESULTS: Uninephrectomized male C57BL/6J mice were randomized to vehicle subcutaneus, Ang II (1 mug/h) subcutaneous, vehicle+PAI-039 (1 mg/g chow), or Ang II+PAI-039 during high-salt intake for 8 weeks. Ang II caused significant medial, adventitial, and aortic wall thickening compared with vehicle. PAI-039 attenuated Ang II-induced aortic remodeling without altering the pressor response to Ang II. Ang II increased heart/body weight ratio and cardiac fibrosis. PAI-039 did not attenuate the effect of Ang II on cardiac hypertrophy and increased fibrosis. The effect of PAI-039 on Ang II/salt-induced aortic remodeling and cardiac fibrosis was comparable to the effect of genetic PAI-1 deficiency. Ang II increased aortic mRNA expression of PAI-1, collagen I, collagen III, fibronectin, osteopontin, monocyte chemoattractant protein-1, and F4/80; PAI-039 significantly decreased the Ang II-induced increase in aortic osteopontin expression at 8 weeks.
CONCLUSIONS: This study demonstrates that pharmacological inhibition of PAI-1 protects against Ang II-induced aortic remodeling. Future studies are needed to determine whether the interactive effect of Ang II/salt and reduced PAI-1 activity on cardiac fibrosis is species-specific. In this study, the effect of pharmacological PAI-1 inhibition in a mouse model of Ang II-induced vascular remodeling and cardiac fibrosis was examined. PAI-1 inhibition significantly attenuated Ang II-induced aortic medial and wall thickening, but not cardiac hypertrophy, and enhanced Ang II/salt-induced cardiac fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576638     DOI: 10.1161/01.ATV.0000152356.85791.52

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  51 in total

1.  Small Molecule PAI-1 Functional Inhibitor Attenuates Vascular Smooth Muscle Cell Migration and Survival: Implications for the Therapy of Vascular Disease.

Authors:  Tessa M Simone; Paul J Higgins
Journal:  New Horiz Transl Med       Date:  2014-09-01

2.  Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Authors:  Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

Review 3.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

4.  Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis.

Authors:  Wen-Tan Huang; Hasina Akhter; Chunsun Jiang; Mark MacEwen; Qiang Ding; Veena Antony; Victor John Thannickal; Rui-Ming Liu
Journal:  Exp Gerontol       Date:  2014-11-28       Impact factor: 4.032

5.  Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

Authors:  Amanda E Boe; Mesut Eren; Sheila B Murphy; Christine E Kamide; Atsuhiko Ichimura; David Terry; Danielle McAnally; Layton H Smith; Toshio Miyata; Douglas E Vaughan
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

6.  Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?

Authors:  Daniel I Simon; Norman M Simon
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

7.  Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture.

Authors:  Zhi Xu; Francis J Castellino; Victoria A Ploplis
Journal:  Blood       Date:  2009-12-15       Impact factor: 22.113

8.  A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.

Authors:  Yuko Izuhara; Nagahisa Yamaoka; Hidehiko Kodama; Takashi Dan; Shunya Takizawa; Noriaki Hirayama; Kanji Meguro; Charles van Ypersele de Strihou; Toshio Miyata
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

9.  Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process.

Authors:  Raúl Rodrigues Díez; Raquel Rodrigues-Díez; Carolina Lavoz; Sandra Rayego-Mateos; Esther Civantos; Juan Rodríguez-Vita; Sergio Mezzano; Alberto Ortiz; Jesús Egido; Marta Ruiz-Ortega
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

10.  Orphan nuclear receptor small heterodimer partner inhibits angiotensin II- stimulated PAI-1 expression in vascular smooth muscle cells.

Authors:  Kyeong-Min Lee; Hye-Young Seo; Mi-Kyung Kim; Ae-Kyung Min; Seong-Yeol Ryu; Yoon-Nyun Kim; Young Joo Park; Hueng-Sik Choi; Ki-Up Lee; Wan-Ju Park; Keun-Gyu Park; In-Kyu Lee
Journal:  Exp Mol Med       Date:  2010-01-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.